Innate Pharma highlights abstracts selected for ASCO 2025 annual meeting
Innate Pharma highlights ANKET® abstracts selected for the EHA 2025 congress
Innate Pharma reports first quarter 2025 business update and financial results
Number of shares and voting rights of Innate Pharma as of May 5, 2025
Innate Pharma announces conference call and webcast for Q1 2025 business update
Innate Pharma files its 2024 Universal Registration Document (Document d’enregistrement Universel) and 2024 Annual Report on Form 20-F
Innate Pharma highlights preclinical anti-tumor efficacy data of its antibody drug conjugate IPH4502 at the AACR 2025 annual meeting
Number of shares and voting rights of Innate Pharma as of April 25, 2025
Innate Pharma announces €15m investment by Sanofi
Innate Pharma regains its rights on CD123 targeting ANKET® and announces Sanofi’s intention to make a strategic investment in the Company
